Full article: Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System
![These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval: These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval:](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-26.jpg&id=725911)
These highlights do not include all the information needed to use BUPRENORPHINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for BUPRENORPHINE TRANSDERMAL SYSTEM. BUPRENORPHINE transdermal system, CIII Initial U.S. Approval:
![Butrans® (buprenorphine) Transdermal System CIII | What is Butrans® ( buprenorphine) Transdermal System CIII? Butrans® (buprenorphine) Transdermal System CIII | What is Butrans® ( buprenorphine) Transdermal System CIII?](https://butrans.com/static/chart-what-is-butran-014d52a99ea829a07151c453b165e89b.png)